2014 Q3 Form 10-Q Financial Statement
#000110465914058343 Filed on August 07, 2014
Income Statement
| Concept | 2014 Q3 | 2014 Q2 | 2013 Q2 |
|---|---|---|---|
| Revenue | $1.000M | $934.0K | $1.322M |
| YoY Change | 150.0% | -29.35% | -5.57% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $8.600M | $8.600M | $5.800M |
| YoY Change | -29.98% | 48.28% | -23.68% |
| % of Gross Profit | |||
| Research & Development | $1.900M | $2.125M | $2.412M |
| YoY Change | -94.31% | -11.9% | -91.84% |
| % of Gross Profit | |||
| Depreciation & Amortization | $2.500M | $2.800M | $2.000M |
| YoY Change | 38.89% | 40.0% | 17.65% |
| % of Gross Profit | |||
| Operating Expenses | $10.50M | $10.73M | $8.220M |
| YoY Change | -77.01% | 30.51% | -77.87% |
| Operating Profit | -$9.794M | -$6.898M | |
| YoY Change | 41.98% | -80.68% | |
| Interest Expense | -$12.30M | $10.33M | $3.025M |
| YoY Change | -746.69% | 241.39% | 101.53% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $300.0K | $83.00K | $8.192M |
| YoY Change | -910.81% | -98.99% | |
| Pretax Income | -$21.50M | -$19.87M | -$1.541M |
| YoY Change | 126.32% | 1189.62% | -95.85% |
| Income Tax | -$300.0K | $278.0K | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$21.30M | -$63.60M | -$36.40M |
| YoY Change | -54.68% | 74.73% | -1.89% |
| Net Earnings / Revenue | -2130.0% | -6809.42% | -2753.4% |
| Basic Earnings Per Share | -$0.37 | ||
| Diluted Earnings Per Share | -$188.3K | -$573.0K | -$0.37 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 115.0M shares | 112.6M shares | 97.60M shares |
| Diluted Shares Outstanding | 97.60M shares |
Balance Sheet
| Concept | 2014 Q3 | 2014 Q2 | 2013 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $263.1M | $334.5M | $443.0M |
| YoY Change | -48.02% | -24.5% | 49.92% |
| Cash & Equivalents | $119.6M | $208.1M | $199.2M |
| Short-Term Investments | $143.5M | $126.4M | $243.8M |
| Other Short-Term Assets | $6.300M | $15.20M | $3.600M |
| YoY Change | 53.66% | 322.22% | 5.88% |
| Inventory | $0.00 | $0.00 | $8.240M |
| Prepaid Expenses | |||
| Receivables | $4.000M | $0.00 | $2.200M |
| Other Receivables | $0.00 | $0.00 | $200.0K |
| Total Short-Term Assets | $273.5M | $353.2M | $457.2M |
| YoY Change | -47.64% | -22.76% | 50.7% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $100.0K | $0.00 | $8.952M |
| YoY Change | -98.83% | -100.0% | -7.71% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $30.00M | ||
| YoY Change | |||
| Long-Term Investments | $47.80M | $34.30M | $90.30M |
| YoY Change | -45.87% | -62.02% | 8.53% |
| Other Assets | $20.80M | $22.39M | $7.372M |
| YoY Change | 249.82% | 203.65% | 154.21% |
| Total Long-Term Assets | $280.2M | $252.4M | $137.5M |
| YoY Change | 95.02% | 83.64% | 43.2% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $273.5M | $353.2M | $457.2M |
| Total Long-Term Assets | $280.2M | $252.4M | $137.5M |
| Total Assets | $553.7M | $605.6M | $594.7M |
| YoY Change | -16.86% | 1.83% | 48.9% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $10.60M | $1.799M | $4.834M |
| YoY Change | 84.89% | -62.78% | -3.32% |
| Accrued Expenses | $24.40M | $16.90M | $24.80M |
| YoY Change | 4.72% | -31.85% | 65.33% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $36.10M | $49.99M | $38.65M |
| YoY Change | -6.62% | 29.36% | 49.79% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $705.1M | $737.5M | $460.0M |
| YoY Change | 145.25% | 60.33% | 166.67% |
| Other Long-Term Liabilities | $5.600M | $1.300M | $10.50M |
| YoY Change | -42.86% | -87.62% | -11.76% |
| Total Long-Term Liabilities | $710.7M | $1.300M | $470.5M |
| YoY Change | 139.05% | -99.72% | 155.15% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $36.10M | $49.99M | $38.65M |
| Total Long-Term Liabilities | $710.7M | $1.300M | $470.5M |
| Total Liabilities | $746.8M | $51.29M | $509.1M |
| YoY Change | 122.26% | -89.92% | 142.2% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.636B | -$1.408B | |
| YoY Change | 16.2% | ||
| Common Stock | $1.445B | $1.494B | |
| YoY Change | -3.26% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$193.1M | -$187.5M | $85.65M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $553.7M | $605.6M | $594.7M |
| YoY Change | -16.86% | 1.83% | 48.9% |
Cashflow Statement
| Concept | 2014 Q3 | 2014 Q2 | 2013 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$21.30M | -$63.60M | -$36.40M |
| YoY Change | -54.68% | 74.73% | -1.89% |
| Depreciation, Depletion And Amortization | $2.500M | $2.800M | $2.000M |
| YoY Change | 38.89% | 40.0% | 17.65% |
| Cash From Operating Activities | -$21.10M | -$54.40M | -$16.70M |
| YoY Change | -48.91% | 225.75% | -51.45% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$25.00M | -$44.00M | -$30.70M |
| YoY Change | 142.72% | 43.32% | 4285.71% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$34.60M | $32.70M | -$42.80M |
| YoY Change | -61.3% | -176.4% | 31.69% |
| Cash From Investing Activities | -$59.50M | -$11.20M | -$73.50M |
| YoY Change | -40.32% | -84.76% | 122.05% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -7.900M | 148.4M | 23.40M |
| YoY Change | -106.96% | 534.19% | -89.08% |
| NET CHANGE | |||
| Cash From Operating Activities | -21.10M | -54.40M | -16.70M |
| Cash From Investing Activities | -59.50M | -11.20M | -73.50M |
| Cash From Financing Activities | -7.900M | 148.4M | 23.40M |
| Net Change In Cash | -88.50M | 82.80M | -66.80M |
| YoY Change | 221.82% | -223.95% | -145.54% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$21.10M | -$54.40M | -$16.70M |
| Capital Expenditures | -$25.00M | -$44.00M | -$30.70M |
| Free Cash Flow | $3.900M | -$10.40M | $14.00M |
| YoY Change | -112.58% | -174.29% | -141.54% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| thrx |
Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
|
P2Y | ||
| thrx |
Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
|
P7M | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
| CY2014Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
115014166 | shares |
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| us-gaap |
Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Product Revenues</font></i></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We currently have no product revenues following the spin-off of Theravance Biopharma.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Prior to the Spin-Off of Theravance Biopharma, we sold VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> in the U.S. through a limited number of distributors, and title and risk of loss transferred upon receipt of the product by these distributors. Healthcare providers ordered VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> through these distributors. Commencing in the first quarter of 2014, revenue on the sale of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font> <font style="FONT-SIZE: 10pt;" size="2">was recorded on a sell-through basis, once the distributors sold the product to healthcare providers.  As VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> is a product that is sold by Theravance Biopharma, the revenue from product sales are included within discontinued operations in the consolidated statements of operations for the three and six months ended June 30, 2014.  There was no revenue from product sales for any period in 2013.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Product</font> <font style="FONT-SIZE: 10pt;" size="2">sales</font> <font style="FONT-SIZE: 10pt;" size="2">were</font> <font style="FONT-SIZE: 10pt;" size="2">recorded</font> <font style="FONT-SIZE: 10pt;" size="2">net</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">estimated</font> <font style="FONT-SIZE: 10pt;" size="2">government-mandated</font> <font style="FONT-SIZE: 10pt;" size="2">rebates</font> <font style="FONT-SIZE: 10pt;" size="2">and</font> <font style="FONT-SIZE: 10pt;" size="2">chargebacks,</font> <font style="FONT-SIZE: 10pt;" size="2">distribution</font> <font style="FONT-SIZE: 10pt;" size="2">fees,</font> <font style="FONT-SIZE: 10pt;" size="2">estimated</font> <font style="FONT-SIZE: 10pt;" size="2">product</font> <font style="FONT-SIZE: 10pt;" size="2">returns</font> <font style="FONT-SIZE: 10pt;" size="2">and</font> <font style="FONT-SIZE: 10pt;" size="2">other</font> <font style="FONT-SIZE: 10pt;" size="2">deductions.</font> <font style="FONT-SIZE: 10pt;" size="2">We</font> <font style="FONT-SIZE: 10pt;" size="2">reflected</font> <font style="FONT-SIZE: 10pt;" size="2">such</font> <font style="FONT-SIZE: 10pt;" size="2">reductions</font> <font style="FONT-SIZE: 10pt;" size="2">in</font> <font style="FONT-SIZE: 10pt;" size="2">revenue</font> <font style="FONT-SIZE: 10pt;" size="2">either</font> <font style="FONT-SIZE: 10pt;" size="2">as</font> <font style="FONT-SIZE: 10pt;" size="2">an</font> <font style="FONT-SIZE: 10pt;" size="2">allowance</font> <font style="FONT-SIZE: 10pt;" size="2">to</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">related</font> <font style="FONT-SIZE: 10pt;" size="2">account</font> <font style="FONT-SIZE: 10pt;" size="2">receivable</font> <font style="FONT-SIZE: 10pt;" size="2">from</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">distributor,</font> <font style="FONT-SIZE: 10pt;" size="2">or</font> <font style="FONT-SIZE: 10pt;" size="2">as</font> <font style="FONT-SIZE: 10pt;" size="2">an</font> <font style="FONT-SIZE: 10pt;" size="2">accrued</font> <font style="FONT-SIZE: 10pt;" size="2">liability,</font> <font style="FONT-SIZE: 10pt;" size="2">depending</font> <font style="FONT-SIZE: 10pt;" size="2">on</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">nature</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">sales</font> <font style="FONT-SIZE: 10pt;" size="2">deduction.</font> <font style="FONT-SIZE: 10pt;" size="2">Sales</font> <font style="FONT-SIZE: 10pt;" size="2">deductions</font> <font style="FONT-SIZE: 10pt;" size="2">were</font> <font style="FONT-SIZE: 10pt;" size="2">based</font> <font style="FONT-SIZE: 10pt;" size="2">on</font> <font style="FONT-SIZE: 10pt;" size="2">management’s</font> <font style="FONT-SIZE: 10pt;" size="2">estimates</font> <font style="FONT-SIZE: 10pt;" size="2">that</font> <font style="FONT-SIZE: 10pt;" size="2">considered</font> <font style="FONT-SIZE: 10pt;" size="2">payer</font> <font style="FONT-SIZE: 10pt;" size="2">mix</font> <font style="FONT-SIZE: 10pt;" size="2">in</font> <font style="FONT-SIZE: 10pt;" size="2">target</font> <font style="FONT-SIZE: 10pt;" size="2">markets,</font> <font style="FONT-SIZE: 10pt;" size="2">industry</font> <font style="FONT-SIZE: 10pt;" size="2">benchmarks</font> <font style="FONT-SIZE: 10pt;" size="2">and</font> <font style="FONT-SIZE: 10pt;" size="2">experience</font> <font style="FONT-SIZE: 10pt;" size="2">to</font> <font style="FONT-SIZE: 10pt;" size="2">date.</font> <font style="FONT-SIZE: 10pt;" size="2">We</font> <font style="FONT-SIZE: 10pt;" size="2">monitored</font> <font style="FONT-SIZE: 10pt;" size="2">inventory</font> <font style="FONT-SIZE: 10pt;" size="2">levels</font> <font style="FONT-SIZE: 10pt;" size="2">in</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">distribution</font> <font style="FONT-SIZE: 10pt;" size="2">channel,</font> <font style="FONT-SIZE: 10pt;" size="2">as</font> <font style="FONT-SIZE: 10pt;" size="2">well</font> <font style="FONT-SIZE: 10pt;" size="2">as</font> <font style="FONT-SIZE: 10pt;" size="2">sales</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 8pt;" size="1"> </font><font style="FONT-SIZE: 10pt;" size="2">by</font> <font style="FONT-SIZE: 10pt;" size="2">distributors</font> <font style="FONT-SIZE: 10pt;" size="2">to</font> <font style="FONT-SIZE: 10pt;" size="2">healthcare</font> <font style="FONT-SIZE: 10pt;" size="2">providers,</font> <font style="FONT-SIZE: 10pt;" size="2">using</font> <font style="FONT-SIZE: 10pt;" size="2">product-specific</font> <font style="FONT-SIZE: 10pt;" size="2">data</font> <font style="FONT-SIZE: 10pt;" size="2">provided</font> <font style="FONT-SIZE: 10pt;" size="2">by</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">distributors.</font> <font style="FONT-SIZE: 10pt;" size="2">Product</font> <font style="FONT-SIZE: 10pt;" size="2">return</font> <font style="FONT-SIZE: 10pt;" size="2">allowances</font> <font style="FONT-SIZE: 10pt;" size="2">were</font> <font style="FONT-SIZE: 10pt;" size="2">based</font> <font style="FONT-SIZE: 10pt;" size="2">on</font> <font style="FONT-SIZE: 10pt;" size="2">amounts</font> <font style="FONT-SIZE: 10pt;" size="2">owed</font> <font style="FONT-SIZE: 10pt;" size="2">or</font> <font style="FONT-SIZE: 10pt;" size="2">to</font> <font style="FONT-SIZE: 10pt;" size="2">be</font> <font style="FONT-SIZE: 10pt;" size="2">claimed</font> <font style="FONT-SIZE: 10pt;" size="2">on</font> <font style="FONT-SIZE: 10pt;" size="2">related</font> <font style="FONT-SIZE: 10pt;" size="2">sales.</font> <font style="FONT-SIZE: 10pt;" size="2">These</font> <font style="FONT-SIZE: 10pt;" size="2">estimates</font> <font style="FONT-SIZE: 10pt;" size="2">took</font> <font style="FONT-SIZE: 10pt;" size="2">into</font> <font style="FONT-SIZE: 10pt;" size="2">consideration</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">terms</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">our</font> <font style="FONT-SIZE: 10pt;" size="2">agreements</font> <font style="FONT-SIZE: 10pt;" size="2">with</font> <font style="FONT-SIZE: 10pt;" size="2">customers,</font> <font style="FONT-SIZE: 10pt;" size="2">historical</font> <font style="FONT-SIZE: 10pt;" size="2">product</font> <font style="FONT-SIZE: 10pt;" size="2">returns</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 8pt;" size="1"> </font><font style="FONT-SIZE: 10pt;" size="2">experienced</font> <font style="FONT-SIZE: 10pt;" size="2">by</font> <font style="FONT-SIZE: 10pt;" size="2">our</font> <font style="FONT-SIZE: 10pt;" size="2">former</font> <font style="FONT-SIZE: 10pt;" size="2">collaborative</font> <font style="FONT-SIZE: 10pt;" size="2">partner,</font> <font style="FONT-SIZE: 10pt;" size="2">Astellas</font> <font style="FONT-SIZE: 10pt;" size="2">Pharma,</font> <font style="FONT-SIZE: 10pt;" size="2">Inc.</font> <font style="FONT-SIZE: 10pt;" size="2">(“Astellas”),</font> <font style="FONT-SIZE: 10pt;" size="2">rebates</font> <font style="FONT-SIZE: 10pt;" size="2">or</font> <font style="FONT-SIZE: 10pt;" size="2">discounts</font> <font style="FONT-SIZE: 10pt;" size="2">taken,</font> <font style="FONT-SIZE: 10pt;" size="2">estimated</font> <font style="FONT-SIZE: 10pt;" size="2">levels</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">inventory</font> <font style="FONT-SIZE: 10pt;" size="2">in</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">distribution</font> <font style="FONT-SIZE: 10pt;" size="2">channel,</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">shelf</font> <font style="FONT-SIZE: 10pt;" size="2">life</font> <font style="FONT-SIZE: 10pt;" size="2">of</font> <font style="FONT-SIZE: 10pt;" size="2">the</font> <font style="FONT-SIZE: 10pt;" size="2">product,</font> <font style="FONT-SIZE: 10pt;" size="2">and</font> <font style="FONT-SIZE: 10pt;" size="2">specific</font> <font style="FONT-SIZE: 10pt;" size="2">known</font> <font style="FONT-SIZE: 10pt;" size="2">market</font> <font style="FONT-SIZE: 10pt;" size="2">events,</font> <font style="FONT-SIZE: 10pt;" size="2">such</font> <font style="FONT-SIZE: 10pt;" size="2">as</font> <font style="FONT-SIZE: 10pt;" size="2">competitive</font> <font style="FONT-SIZE: 10pt;" size="2">pricing</font> <font style="FONT-SIZE: 10pt;" size="2">and</font> <font style="FONT-SIZE: 10pt;" size="2">new</font> <font style="FONT-SIZE: 10pt;" size="2">product</font> <font style="FONT-SIZE: 10pt;" size="2">introductions.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Sales Discounts:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We offered cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. We expected our customers to comply with the prompt payment terms to earn the cash discount. We accounted for cash discounts by reducing accounts receivable by the full amount and recognizing the discount as a reduction of revenue in the same period the related revenue is recognized.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Chargebacks and Government Rebates:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  For VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> sales in the U.S., we estimated reductions to product sales for qualifying federal and state government programs including discounted pricing offered to Public Health Service (PHS) as well as government-managed Medicaid programs. Our reduction for PHS was based on actual chargebacks that distributors have claimed for reduced pricing offered to such health care providers. Our accrual for Medicaid was based upon statutorily-defined discounts, estimated payer mix, expected sales to qualified healthcare providers, and our expectation about future utilization. The Medicaid accrual and government rebates that were invoiced directly to us were recorded in other accrued liabilities on the consolidated balance sheet. For qualified programs that purchased our products through distributors at a lower contractual government price, the distributors charged back to us the difference between their acquisition cost and the lower contractual government price, which we recorded as an allowance against accounts receivable.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Distribution Fees and Product Returns:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We had written contracts with our distributors that include terms for distribution-related fees. We recorded distribution-related fees based on a percentage of the product sales price. We offered our distributors a right to return product purchased directly from us, which was principally based upon the product’s expiration date. Additionally, we had granted more expansive return rights to our distributors following our product launch of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2">. Our policy was to accept returns for expired product during the six months prior to and twelve months after the product expiration date on product that had been sold to our distributors. We developed estimates for VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> product returns based upon historical VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> sales from our former collaborative partner, Astellas. We recorded distribution fees and product returns as an allowance against accounts receivable.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Allowance for Doubtful Accounts:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We maintained a policy to record allowances for potentially doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. As of June 30, 2014 and December 31, 2013, there were no allowances for doubtful accounts as we have not had any write-offs historically.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> </div> | ||
| CY2014Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
4329000 | USD |
| CY2014Q2 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
450000000 | USD |
| CY2014Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1300000 | USD |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
0 | USD |
| CY2014Q2 | thrx |
Contribution Of Cash And Cash Equivalents And Marketable Securities In Business Separation
ContributionOfCashAndCashEquivalentsAndMarketableSecuritiesInBusinessSeparation
|
393000000 | USD |
| CY2014Q2 | thrx |
Common Stock Stock Dividend Ratio
CommonStockStockDividendRatio
|
0.286 | pure |
| thrx |
Federal Statutory Tax Effect Of Gain Loss On Distribution Of Assets Business Separation
FederalStatutoryTaxEffectOfGainLossOnDistributionOfAssetsBusinessSeparation
|
400000000 | USD | |
| CY2014Q2 | us-gaap |
Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
|
2184000 | USD |
| CY2013Q2 | us-gaap |
Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
|
5000 | USD |
| us-gaap |
Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
|
3129000 | USD | |
| us-gaap |
Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
|
27000 | USD | |
| dei |
Entity Registrant Name
EntityRegistrantName
|
THERAVANCE INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001080014 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-06-30 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| us-gaap |
Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Royalties</font></i></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We recognize royalty revenue on licensee net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned and reported to us and collectability is reasonably assured.  Royalties are recognized net of amortization of intangible assets associated with any approval and launch milestone payments made to GSK.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> </div> | ||
| us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P15Y | ||
| CY2014Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
0 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2013Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
5138000 | USD |
| CY2014Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
0 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
360000 | USD |
| CY2014Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
0 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4908000 | USD |
| CY2014Q2 | us-gaap |
Inventory Net
InventoryNet
|
0 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
10406000 | USD |
| CY2014Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-63564000 | USD |
| CY2013Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-36429000 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-131267000 | USD | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-73789000 | USD | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
113163000 | shares |
| CY2013Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
100316000 | shares |
| us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
112608000 | shares | |
| us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
99677000 | shares | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2189000 | shares |
| CY2013Q2 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2713000 | shares |
| us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2189000 | shares | |
| us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2713000 | shares | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
110974000 | shares |
| CY2013Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
97603000 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
110419000 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
96964000 | shares | |
| CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.57 | |
| CY2013Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.19 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.76 | ||
| CY2013Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
20863000 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
20162000 | shares | |
| CY2013Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
502831000 | USD |
| CY2014Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2014Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
346600000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
502669000 | USD |
| CY2013Q4 | thrx |
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
172000 | USD |
| CY2013Q4 | thrx |
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
10000 | USD |
| CY2014Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
342894000 | USD |
| CY2014Q2 | thrx |
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
3722000 | USD |
| CY2014Q2 | thrx |
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
16000 | USD |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
5000000 | USD | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
17600000 | USD | |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
124257000 | USD |
| CY2014Q2 | thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
271000 | USD |
| CY2013Q2 | thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
1322000 | USD |
| thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
541000 | USD | |
| thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
2644000 | USD | |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
10900000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
13000000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
13000000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
13000000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
13000000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
136400000 | USD |
| CY2014Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7747000 | USD |
| CY2013Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7162000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
21281000 | USD | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13257000 | USD | |
| CY2014Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
78000 | USD |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
95000 | USD | |
| CY2013Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
28000 | USD |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
170000 | USD | |
| CY2013Q2 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-34888000 | USD |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
|
1200000 | USD |
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-61502000 | USD | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
79000 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
12.89 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1000000 | USD | |
| CY2014Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
208052000 | USD |
| CY2014Q2 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
126424000 | USD |
| CY2014Q2 | thrx |
Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
|
3473000 | USD |
| CY2014Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
982000 | USD |
| CY2014Q2 | us-gaap |
Assets Current
AssetsCurrent
|
353163000 | USD |
| CY2014Q2 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
34349000 | USD |
| CY2014Q2 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
833000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
194880000 | USD |
| CY2014Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
22385000 | USD |
| CY2014Q2 | us-gaap |
Assets
Assets
|
605610000 | USD |
| CY2014Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1799000 | USD |
| CY2014Q2 | thrx |
Due To A Related Party One Current
DueToARelatedPartyOneCurrent
|
15000000 | USD |
| CY2014Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1023000 | USD |
| CY2014Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
11013000 | USD |
| CY2014Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4834000 | USD |
| CY2014Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1082000 | USD |
| CY2014Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
49994000 | USD |
| CY2014Q2 | us-gaap |
Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
|
287500000 | USD |
| CY2014Q2 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
13000 | USD |
| CY2014Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
1133000 | USD |
| CY2014Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1444105000 | USD |
| CY2014Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
3706000 | USD |
| CY2014Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1636470000 | USD |
| CY2014Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-187526000 | USD |
| CY2014Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
605610000 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
143510000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
321615000 | USD |
| us-gaap |
Revenues
Revenues
|
154000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4812000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
19859000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
24671000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24517000 | USD | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
80000 | USD | |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
199000 | USD |
| CY2013Q4 | thrx |
Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
|
3181000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4287000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
483198000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
55374000 | USD |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
833000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10238000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
7355000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
681255000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7583000 | USD |
| CY2013Q4 | thrx |
Due To A Related Party One Current
DueToARelatedPartyOneCurrent
|
40000000 | USD |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10881000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9714000 | USD |
| CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
2800000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4137000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
9289000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
84404000 | USD |
| CY2013Q4 | us-gaap |
Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
|
287500000 | USD |
| CY2013Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
4774000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
5455000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1115000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1803048000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
162000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1505203000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
299122000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
681255000 | USD |
| CY2013Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
2247000 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
89000 | USD |
| CY2014Q2 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
3473000 | USD |
| CY2014Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
111516000 | shares |
| CY2014Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
113285000 | shares |
| CY2014Q2 | thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
663000 | USD |
| CY2014Q2 | us-gaap |
Revenues
Revenues
|
934000 | USD |
| CY2014Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2125000 | USD |
| CY2014Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8603000 | USD |
| CY2014Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
10728000 | USD |
| CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9794000 | USD |
| CY2014Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
83000 | USD |
| CY2014Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
165000 | USD |
| CY2014Q2 | us-gaap |
Interest Expense
InterestExpense
|
10327000 | USD |
| CY2013Q2 | us-gaap |
Revenues
Revenues
|
1322000 | USD |
| CY2013Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2412000 | USD |
| CY2013Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5808000 | USD |
| CY2013Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
8220000 | USD |
| CY2013Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6898000 | USD |
| CY2013Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
8192000 | USD |
| CY2013Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
190000 | USD |
| CY2013Q2 | us-gaap |
Interest Expense
InterestExpense
|
3025000 | USD |
| thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
-387000 | USD | |
| CY2014Q2 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-43413000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-127723000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-73903000 | USD | |
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
353000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
5761000 | USD | |
| CY2014Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2598000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
11971000 | USD | |
| us-gaap |
Revenues
Revenues
|
2644000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4451000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11864000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | USD | |
| CY2014Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
3535000 | USD |
| CY2013Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-107000 | USD |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
3544000 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6190000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
21281000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
16315000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13671000 | USD | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
6770000 | USD | |
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
375000 | USD | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
2000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4378000 | USD | |
| CY2013Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | USD |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-74000 | USD | |
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-114000 | USD | |
| CY2014Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-60029000 | USD |
| CY2013Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-36536000 | USD |
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
294000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
177000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1908000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
411000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-5832000 | USD | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1874000 | USD | |
| us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
-8213000 | USD | |
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-183000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-2640000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-105042000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
556000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
142861000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
241173000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
100000000 | USD | |
| us-gaap |
Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
|
140000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
2896000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
23786000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
166688000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
64542000 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2036000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13257000 | USD | |
| us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-1422000 | USD | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
3000 | USD | |
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
1169000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-357000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2533000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1026000 | USD | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2941000 | USD | |
| us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
-2540000 | USD | |
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
376000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
4120000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-48317000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1431000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
211797000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
106983000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
30000000 | USD | |
| us-gaap |
Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
|
100000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-118545000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
26433000 | USD | |
| us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
36800000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
271256000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
104394000 | USD | |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
94849000 | USD |
| CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
199243000 | USD |
| us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-12287000 | USD | |
| CY2014Q2 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
|
-43413000 | USD |
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
|
-94934000 | USD | |
| us-gaap |
Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
|
1412000 | USD | |
| us-gaap |
Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
|
1854000 | USD | |
| us-gaap |
Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
|
277541000 | USD | |
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-94934000 | USD | |
| CY2014Q2 | thrx |
Due To A Related Party Two Current
DueToARelatedPartyTwoCurrent
|
15243000 | USD |
| CY2014Q2 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-20151000 | USD |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-1541000 | USD |
| us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-36333000 | USD | |
| thrx |
Transfer Of Net Assets Business Separation
TransferOfNetAssetsBusinessSeparation
|
125337000 | USD | |
| us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
-14234000 | USD | |
| CY2013Q2 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
|
-34888000 | USD |
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
|
-61502000 | USD | |
| CY2014Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.18 | |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.02 | |
| us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.33 | ||
| us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.13 | ||
| CY2014Q2 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
-0.39 | |
| CY2013Q2 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
-0.35 | |
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
-0.86 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
-0.63 | ||
| CY2014Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
0 | USD |
| CY2014Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
0 | USD |
| us-gaap |
Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
|
434677000 | USD | |
| us-gaap |
Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
|
281623000 | USD | |
| CY2014Q2 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
14232000 | USD |
| us-gaap |
Increase Decrease In Due To Affiliates Current
IncreaseDecreaseInDueToAffiliatesCurrent
|
0 | USD | |
| CY2014Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
24005000 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23811000 | shares | |
| us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-100000000 | USD | |
| CY2014Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-19873000 | USD |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1541000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-36055000 | USD | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12287000 | USD | |
| CY2014Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
278000 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
278000 | USD | |
| thrx |
Royalty Revenue From Related Party Gross
RoyaltyRevenueFromRelatedPartyGross
|
3991000 | USD | |
| us-gaap |
Increase Decrease In Due To Affiliates Current
IncreaseDecreaseInDueToAffiliatesCurrent
|
-1738000 | USD | |
| CY2014Q2 | thrx |
Royalty Revenue From Related Party Gross
RoyaltyRevenueFromRelatedPartyGross
|
3261000 | USD |
| us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
1300000 | USD | |
| CY2013Q4 | thrx |
Due To A Related Party Two Current
DueToARelatedPartyTwoCurrent
|
0 | USD |
| CY2014Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
0 | USD |
| CY2013Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
0 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
0 | USD |
| us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
0 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | USD | |
| CY2013Q2 | thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
0 | USD |
| thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
0 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | USD | |
| us-gaap |
Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
|
0 | USD | |
| us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
0 | USD | |
| us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
0 | USD | |
| thrx |
Transfer Of Net Assets Business Separation
TransferOfNetAssetsBusinessSeparation
|
0 | USD | |
| us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
0 | USD | |
| thrx |
Deferred Tax Assets Gross Transferred Spin Off
DeferredTaxAssetsGrossTransferredSpinOff
|
9000000 | USD | |
| CY2013Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD | |
| CY2013Q2 | thrx |
Royalty Revenue From Related Party Gross
RoyaltyRevenueFromRelatedPartyGross
|
0 | USD |
| thrx |
Royalty Revenue From Related Party Gross
RoyaltyRevenueFromRelatedPartyGross
|
0 | USD |
